Olema Pharmaceuticals (OLMA) Operating Income (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Operating Income for 7 consecutive years, with -$58.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Income fell 66.28% year-over-year to -$58.0 million; the TTM figure through Mar 2026 stood at -$201.8 million (down 41.33% YoY), while the FY2025 annual figure was -$178.7 million, down 25.62% from the prior year.
• Operating Income declined to -$58.0 million in Q1 2026 per OLMA's latest filing, from -$50.1 million in the prior quarter.
• Across five years, Operating Income topped out at -$21.6 million in Q2 2023 and bottomed at -$58.0 million in Q1 2026.
• Historically, Operating Income has averaged -$34.8 million across 5 years, with a median of -$33.5 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Income sank 101.51% — and 2023, when it jumped 35.12%.
• Olema Pharmaceuticals' Operating Income stood at -$27.2 million in 2022, then slipped by 11.75% to -$30.4 million in 2023, then retreated by 20.88% to -$36.8 million in 2024, then tumbled by 36.22% to -$50.1 million in 2025, then declined by 15.78% to -$58.0 million in 2026.
• Business Quant data shows OLMA's Operating Income at -$58.0 million in Q1 2026, -$50.1 million in Q4 2025, and -$45.9 million in Q3 2025.